RxDoctor Payments Data

Lee Novick, MD

Ophthalmology · Fountain Valley, CANPI 1366500456

Payments from drug & device makers

$10,535in general payments, 2019–2025

Across 209 payments — averaging $50.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • Carl Zeiss Meditec, Inc.$2K
  • Glaukos Corporation$888
  • Johnson & Johnson Surgical Vision, Inc.$811
  • Rxsight Inc$661
  • AbbVie$563
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$8,63882%
  • Gifts$390%
  • Other$1,85918%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,535 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$245,794
Medicare patients
534
Services billed
2,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost149$94,182
RestasisCyclosporine72$63,337
BesivanceBesifloxacin Hcl123$26,949
Lotemax SmLoteprednol Etabonate101$24,981
XiidraLifitegrast12$22,869
Cyclosporine42$21,377
ProlensaBromfenac Sodium66$19,584
Alphagan PBrimonidine Tartrate37$19,003
VyzultaLatanoprostene Bunod34$17,909
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol80$17,395
RhopressaNetarsudil Mesylate21$15,456
Prednisolone Acetate475$12,104
Brimonidine Tartrate229$11,337
CombiganBrimonidine Tartrate/Timolol30$11,231
Latanoprost728$10,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$563$187,753288 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Lotemax Sm, Prolensa$150$71,514290 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$464$40,77846 claims
AlconAzopt, Simbrinza$3,374$15,75138 claims
Aerie Pharmaceuticals, Inc.Rhopressa$86$15,45621 claims
NovartisTravatan Z$97$8,40212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →